Table 1. Baseline characteristics of HCC patients in the training and validation cohorts.
| Baseline characteristics | Training cohort, n=256 (%) | Validation cohort, n=147 (%) | P value |
|---|---|---|---|
| Age (years) (≤50) | 53 (20.70) | 46 (31.29) | 0.024 |
| Gender (male) | 49 (19.14) | 26 (17.69 | 0.820 |
| HBV (yes) | 207 (80.86) | 122 (83.00) | 0.690 |
| Tumor number (single) | 147 (57.42) | 73 (49.66) | 0.161 |
| Max size (≤3 cm) | 147 (57.42) | 94 (63.95) | 0.238 |
| Cirrhosis (yes) | 233 (91.02) | 134 (91.16) | 1.000 |
| CTP (A) | 252 (98.44) | 146 (99.32) | 0.762 |
| MELD (≤4.81) | 136 (53.13) | 68 (46.26) | 0.221 |
| ALBI grade | 0.512 | ||
| 1 | 131 (51.17) | 72 (48.98) | NA |
| 2 | 120 (46.88) | 74 (50.34) | NA |
| 3 | 5 (1.95) | 1 (0.68) | NA |
| AFP (≤20 ng/mL) | 148 (57.81) | 83 (56.46) | 0.874 |
| ALB (≤43.2 g/L) | 212 (82.81) | 115 (78.23) | 0.318 |
| ALT (≤40 U/L) | 191 (74.61) | 113 (76.87) | 0.698 |
| AST (≤40 U/L) | 215 (83.98) | 123 (83.67) | 1.000 |
| γ-GT (≤60 U/L) | 167 (65.23) | 93 (63.27) | 1.000 |
| TBIL (≤17.1 μmol/L) | 159 (62.11) | 98 (66.67) | 0.419 |
| NLR (≤3) | 113 (44.14) | 78 (53.06) | 0.105 |
| SII (≤324.55) | 101 (39.45) | 63 (42.86) | 0.573 |
| PLR (≤125.28) | 98 (38.28) | 46 (31.29) | 0.193 |
| PNI (≤52.21) | 224 (87.5) | 128 (87.07) | 1.000 |
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; CTP, Child-Turcotte-Pugh; MELD, Model for End-Stage Liver Disease; AFP, alpha-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartic transaminase; γ-GT, γ-glutamyl transpeptidase; TBIL, total bilirubin; NLR, neutrophil lymphocyte ratio; SII, systemic immune inflammatory index; PLR, platelet lymphocyte ratio; PNI, prognostic nutritional index.